Maynard, MA, United States of America

John Kane

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 14.0

ph-index = 4

Forward Citations = 43(Granted Patents)


Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: John Kane: Innovator in Pharmaceutical Development

Introduction

John Kane is a notable inventor based in Maynard, MA (US), recognized for his contributions to pharmaceutical innovations. With a total of six patents to his name, Kane has made significant strides in the field of medicine, particularly in the treatment of complex diseases.

Latest Patents

Kane's latest patents focus on 2-acylaminopropoanol-type glucosylceramide synthase inhibitors. These compounds are designed for use in treating polycystic kidney disease and are represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions developed by Kane include methods for administering these compounds to subjects in need, ensuring a therapeutically effective amount is delivered. His work also addresses conditions such as type 2 diabetes, renal hypertrophy, and various lysosomal storage diseases, including Tay-Sachs, Gaucher's, and Fabry's disease.

Career Highlights

Kane is currently associated with Genzyme Corporation, where he continues to innovate and develop new therapeutic solutions. His work has been instrumental in advancing treatments that target critical health issues, showcasing his commitment to improving patient outcomes.

Collaborations

Kane has collaborated with esteemed colleagues, including Craig S. Siegel and Cecilia M. Bastos, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

John Kane's contributions to pharmaceutical development through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in the treatment of serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…